The abstract is read at the publisher; the summary is JClub's.
Ixekizumab plus tirzepatide maintained and expanded psoriatic arthritis control through week 52, with simultaneous ACR50 and ≥10% weight reduction rising to 39.2% vs 1.7%.
- Why it matters: Obesity or overweight is common in psoriatic arthritis, and prior week 36 results suggested added benefit; this report tests whether that disease control and safety persist to week 52.
- What they did: In TOGETHER-PsA (NCT06588296), adults with active PsA and obesity or overweight were randomized 1:1 to ixekizumab plus tirzepatide or ixekizumab alone, with week 52 outcomes including ACR50, weight, metabolic, and safety measures.
- The result: ACR50 diverged after week 36, reaching 43.7% vs 15.7% at week 52, alongside improvements across multiple disease, patient-reported, and metabolic outcomes, with safety consistent with prior studies and no new concerns.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.